News for argenx SE (ARGNF)

**media[559807]**

On March 7, 2025, argenx SE (ARGX), a global immunology company, announced the presentation of clinical trial and real-world data for its products VYVGART® and

Product Net Sales: $737 million for Q4 and $2.2 billion for the full year 2024.Total Operating Income: $761 million for Q4 and $2.3 billion for the full year 2

Feb 27, 2025 / 01:30PM GMTOperator Good morning. My name is Rob, and I will be your conference operator today. I would like to welcome everyone to the call. (Op

argenx SE (NASDAQ:ARGX) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ETCompany ParticipantsBeth DelGiacco - Vice President, Corporate...

**media[551690]**

On February 27, 2025, argenx SE (ARGX), a global immunology company, announced its financial results for the full year 2024, highlighting significant achievemen

$737 million in fourth quarter and $2.2 billion in full year global product net sales Received positive CHMP recommendation for VYVGART pre-filled syringe for

On February 25, 2025, argenx SE (ARGX), a prominent global immunology company, announced that its CEO, Tim Van Hauwermeiren, will present at the TD Cowen 45th A

Baron Global Advantage Fund advanced during the fourth quarter of 2024, outperforming its benchmark, the MSCI ACWI Index. Read more here.

Baron Funds, an investment management company, released its “Baron Health Care Fund” fourth quarter 2024 investor letter.

Significant Stock Acquisition by Paradigm Biocapital Advisors LP (Trades, Portfolio) On December 31, 2024, Paradigm Biocapital Advisors LP (Trades, Portfolio) e

On December 31, 2024, Paradigm Biocapital Advisors LP (Trades, Portfolio) executed a significant transaction by acquiring an additional 907,412 shares of Janux

On February 5, 2025, Paradigm Biocapital Advisors LP (Trades, Portfolio) made a significant move by acquiring an additional 950,162 shares of Cogent Biosciences

On December 31, 2024, FMR LLC (Trades, Portfolio), a prominent investment firm, executed a significant transaction by acquiring 6,019,640 shares of argenx SE. T

On January 31, 2025, Deep Track Capital, LP (Trades, Portfolio) made a strategic move by acquiring 3,023,484 shares of Maze Therapeutics Inc. This transaction w

Baron Opportunity Fund increased in the fourth quarter of 2024, outperforming its benchmark, the Russell 3000 Growth Index.

Baron International Growth Fund declined 5.90% (inst.) during the final quarter of 2024. Click here to read the full commentary.

We recently published a list of 12 High Growth International Stocks to Invest in Now.